Norway· NO-ID_19BA071C-66A4-4EFA-B152-61B2E8BFDE1D
Lazcluze
A lazertinib product containing lazertinib mesilate monohydrate, registered in Norway by Janssen-Cilag International N.V.. The same ATC class is registered in 13 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Lazertinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EB09 (lazertinib), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Lazertinib · ATC L01EB09
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lazertinib costs, country by country.
Normalised to the WHO defined daily dose (0.24 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lazertinib · price per daily dose (0.24 g)
USD · FX 28 Sept 2026
- CH Switzerland$339.05
The record
At a glance
FEST (Norway)- Active substance
- Lazertinib Mesilate Monohydrate
- Manufacturer
- Janssen-Cilag International N.V.
- Country
- Norway (NO)
- ATC code
- L01EB09
- ATC class
- Lazertinib
- Defined daily dose
- 0.24 g, O
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_19BA071C-66A4-4EFA-B152-61B2E8BFDE1D
- no_varenummer4653272 x 14NOK 110787.2
- gtin7323281006053
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lazertinib in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaLAZCLUZEJanssen-Cilag International N.V., Beerse
- SwitzerlandLazcluze
- SpainLAZCLUZE 240 MG COMPRIMIDOS RECUBIERTOS CON PELICULAJanssen-Cilag International N.V
- FinlandLazcluzeJanssen Cilag International
- IrelandLazcluze 240 mg film-coated tabletsJanssen-Cilag International NV
- IcelandLazcluzeJanssen-Cilag International NV*
- NetherlandsLazcluze 240 mg filmomhulde tablettenJanssen-Cilag International NV
- PolandLazcluzeJanssen-Cilag International N.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Lazcluze
- Liechtenstein · Lazcluze
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ef6f6070-1c4f-487d-bb9c-c2eb923869af GET /v1/drugs/ef6f6070-1c4f-487d-bb9c-c2eb923869af?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablett, filmdrasjert",
"source": "fest",
"status": "A",
"atc_name": "Lazertinib",
"merkevare_id": "ID_19BA071C-66A4-4EFA-B152-61B2E8BFDE1D",
"name_form_strength": "Lazcluze tab 240 mg",
"prescription_group": "C"
}See everything about lazertinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.